Mankind Pharma announced its July‑to‑September quarter earnings for the financial year 2026‑27, reporting a 39% year‑on‑year rise in consolidated net profit to ₹711 crore, up from ₹512 crore in the corresponding quarter of the previous year. The pharmaceutical company highlighted healthy revenue and margin growth as key drivers of the performance. The company’s core operations revenue increased 17.3% YoY to ₹4,338 crore, compared with ₹3,697 crore in the same quarter of FY25‑26. The earnings release underscored strong growth in both domestic and international business segments as the primary reason for the revenue uptick.

Operating margin improved by 300 basis points to 30% in the second quarter of FY27, up from 27% in the same period of the previous financial year. Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 27.2% YoY to ₹1,175 crore from ₹924 crore. EBITDA margins expanded 210 basis points to 27.1% in the September quarter, from 25% in the second quarter of FY25‑26. The company cited disciplined execution and strengthening business fundamentals as the basis for the margin gains.

Following the release of the Q2 results, Mankind Pharma’s share price rallied 5.4% to an intraday high of ₹2,333.90 before closing at ₹2,312 apiece on Monday, October 26, 2026. This closing price was above the previous market close of ₹2,212.60. The stock’s upward movement reflected investor focus on the company’s robust financial performance and margin improvement in the September quarter. The rally contributed to a 6.8% year‑to‑date return for the shares.

The company’s press release noted that the acquisition of Armed Cell Therapeutics marks a strategic entry into next‑generation CAR‑T therapies, strengthening research and development capabilities for future growth. Mankind Pharma also launched one new product during the quarter, bringing the total number of launched products in the United States to 50. The acquisition and product launch were highlighted as part of the company’s broader strategy to enhance its therapeutic portfolio and international presence.

Domestic revenues grew 15.9% YoY, driven by double‑digit growth in both the Mankind and BSV speciality businesses, and supported by volume outperformance in the Indian pharmaceutical market. The secondary sales segment also contributed to the overall rise in domestic revenues. Internationally, global revenues increased 33% in Q2 FY27, propelled by strong growth in both Mankind and BSV International segments. The company’s international business benefited from robust export performance during the period.

Mankind Pharma’s market capitalisation stood at ₹95,496 crore as of the close on Monday, October 26, 2026. Over the last three years, the shares have delivered nearly 36% returns to investors, while the past year has seen a 4.9% decline. In the last month, the stock has lost 6.5%, but it rose 2.6% in the last week. The shares reached a 52‑week high of ₹2,642 on July 29, 2026, and a 52‑week low of ₹1,909.70 on March 23, 2026.